Orsini Selected as Specialty Pharmacy Partner for ITVISMA® (onasemnogene abeparvovec-brve)
ITVISMA is an FDA-approved intrathecal gene therapy for the treatment of spinal muscular atrophy Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for ITVISMA® (onasemnogene abeparvovec-brve), an FDA-approved intrathecal gene therapy for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years […]